TARS (Tarsus Pharmaceuticals, Inc.) Stock Financials & Earnings

TARSTarsus Pharmaceuticals, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$451M

Net Income (TTM)-$66M

EPS (TTM)-$1.62

Free Cash Flow (TTM)-$22M

Gross Margin89.6%

Op. Margin-15.7%

Net Margin-14.7%

FCF Margin-4.9%

P/S Ratio (TTM)6.9x

P/E Ratio (TTM)—

YoY Rev Growth+146.7%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$3M	$2M	-$25M
Q2 23	$0	-$316K	-$33M
Q3 23	$2M	$1M	-$41M
Q4 23	$13M	$12M	-$44M
Q1 24	$28M	$26M	-$38M
Q2 24	$41M	$38M	-$33M
Q3 24	$48M	$45M	-$25M
Q4 24	$66M	$61M	-$24M
Q1 25	$78M	$73M	-$26M
Q2 25	$103M	$96M	-$22M
Q3 25	$119M	$94M	-$15M
Q4 25	$152M	$141M	-$8M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$12M	—	$15M
Q2 23	$13M	—	$20M
Q3 23	$12M	$30M	—
Q4 23	$13M	—	$43M
Q1 24	$12M	—	$52M
Q2 24	$12M	—	$59M
Q3 24	$12M	—	$58M
Q4 24	$17M	—	$69M
Q1 25	$14M	—	$85M
Q2 25	$16M	—	$103M
Q3 25	$16M	—	$109M
Q4 25	$18M	—	$131M

Revenue Segments

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$66M	$135M	$201M
Q2 23	$107M	$71M	$178M
Q3 23	$227M	$20M	$247M
Q4 23	$225M	$2M	$227M
Q1 24	$194M	$105M	$299M
Q2 24	$181M	$142M	$324M
Q3 24	$176M	$141M	$317M
Q4 24	$95M	$197M	$291M
Q1 25	$176M	$232M	$408M
Q2 25	$97M	$284M	$381M
Q3 25	$113M	$289M	$402M
Q4 25	$184M	$234M	$417M

Shares Outstanding

Revenue Per Employee

Revenue / Employee